The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

BACKGROUND: For patients presenting with an aneurysmal subarachnoid hemorrhage (aSAH), delayed cerebral ischemia (DCI) is a significant cause of morbidity and mortality. The REACT study is designed to assess the safety and efficacy of clazosentan in preventing clinical deterioration due to DCI in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruder, Nicolas, Higashida, Randall, Santin-Janin, Hugues, Dubois, Cécile, Aldrich, E. François, Marr, Angelina, Roux, Sébastien, Mayer, Stephan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763815/
https://www.ncbi.nlm.nih.gov/pubmed/36539711
http://dx.doi.org/10.1186/s12883-022-03002-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763815/
https://www.ncbi.nlm.nih.gov/pubmed/36539711
http://dx.doi.org/10.1186/s12883-022-03002-8

Ejemplares similares